ArticleBreast cancer research and treatment2026
Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCollagen is a defining feature of breast tumors and is increasingly recognized as a regulator of tumor progression and immune exclusion. However, the tumor cell-matrix interaction that link collagen sensing to immune suppression remains poorly understood.
objectivesThe primary objective of this study was to identify the role of integrin α2 (CD49b/ITGA2) in promoting collagen-dependent tumor growth and immune evasion in breast cancer. METHODS &
resultsIntegrated bulk and single cell transcriptomic analyses reveal that ITGA2 is broadly expressed across breast cancer subtypes and is preferentially localized to malignant epithelial cells. Functional assays demonstrate that CD49b is a dominant receptor mediating breast cancer cell adhesion to collagen I and IV. Genetic ablation or antibody-mediated blockade of CD49b suppresses tumor growth in vivo and profoundly remodels the tumor immune microenvironment, characterized by increased infiltration of CD8
conclusionsTogether, these results identify CD49b mediated tumor collagen interactions as a key driver of immune suppression and resistance to immunotherapy, and provide a mechanistic rationale for targeting integrin α2β1 to enhance antitumor immunity in the 4T1 breast cancer model.
Indexed as
Identifiers
42747603What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.